{"entity":{"id":"nct06938321","kind":"trial","name":"A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer","aka":[],"tldr":"A phase 1/2 trial of AK112 in biliary tract cancer, run by Akeso, now recruiting.","summary":"A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer is a phase 1/2 interventional study registered as NCT06938321 by Akeso, with 135 participants planned, started 2025-04-30 and due to reach its primary completion in 2027-05. Interventions recorded: AK112 and AK130.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06938321","url":"https://clinicaltrials.gov/study/NCT06938321"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cholangiocarcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["akeso"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06938321","phase":"1/2","setting":"An Open Label, Multicenter, Phase Ib/II Clinical Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer","sponsor":"Akeso","enrolled":135,"outcomes":[]},"route":"/trials/nct06938321/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"}],"company":[{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/"}]}}